OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
(a) On June 18, 2019, the Registrant held its Annual General Meeting of Shareholders (the “Meeting”).
(b) The final voting results for the Meeting are as follows:
(1) Proposals 1 through 12 were ordinary resolutions, and each proposal was approved as the number of votes cast in favor exceeded the number of votes cast against such proposal.
(2) As a result of Resolution 13 being a Special Resolution, in order for the resolution to be approved by the shareholders, at least 75%, rather than 50%, in nominal value of the outstanding shares entitled to vote for or against the Proposal was required to authorize the resolution. Special Resolution 13 was not approved as it did not achieve the requisite number of votes in favor.
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.
